Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer. - Moore, Kathleen N.; Birrer, Michael J.; Marsters, Jim; Wang, Yulei; Choi, YounJeong; Royer-Joo, Stephanie; Lemahieu, Vanessa; Armstrong, Katy; Cordova, Julie; Samineni, Divya; Schuth, Eva; Vaze, Anjali; et al. (Gynecologic Oncology, 2020)